Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 1039155

Chromogenic anti-FXa assay calibrated with low molecular weight heparin in patients treated with rivaroxaban and apixaban: possibilities and limitations


Margetić, Sandra; Ćelap, Ivana; Delić Brkljačić, Diana; Pavlović, Nikola; Šupraha Goreta, Sandra; Kobasić, Ivana; Lovrenčić- Huzjan, Arijana; Bašić Kes, Vanja
Chromogenic anti-FXa assay calibrated with low molecular weight heparin in patients treated with rivaroxaban and apixaban: possibilities and limitations // Biochemia Medica: The journal of The Croatian Society of Medical Biochemistry and Laboratory Medicine, 30 (2020), 1; 010702, 9 doi:10.11613/BM.2020.010702 (međunarodna recenzija, članak, znanstveni)


CROSBI ID: 1039155 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
Chromogenic anti-FXa assay calibrated with low molecular weight heparin in patients treated with rivaroxaban and apixaban: possibilities and limitations

Autori
Margetić, Sandra ; Ćelap, Ivana ; Delić Brkljačić, Diana ; Pavlović, Nikola ; Šupraha Goreta, Sandra ; Kobasić, Ivana ; Lovrenčić- Huzjan, Arijana ; Bašić Kes, Vanja

Izvornik
Biochemia Medica: The journal of The Croatian Society of Medical Biochemistry and Laboratory Medicine (1330-0962) 30 (2020), 1; 010702, 9

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
apixaban ; DOAC ; factor Xa inhibitors ; LMWH ; rivaroxaban

Sažetak
Introduction: Clinical application of rivaroxaban and apixaban does not require therapeutic monitoring. Commercial anti- activated factor X (anti-FXa) inhibition methods for all anti-FXa drugs are based on the same principle, so there are attempts to evaluate potential clinical application of heparin-calibrated anti-FXa assay as an alternative method for direct FXa inhibitors. We aimed to evaluate relationship between anti- FXa methods calibrated with low molecular weight heparin (LMWH) and with drug specific calibrators, and to determine whether commercial LMWH anti-FXa assay can be used to exclude the presence of clinically relevant concentrations of rivaroxaban and apixaban. Materials and methods: Low molecular weight heparin calibrated reagent (Siemens Healthineers, Marburg, Germany) was used for anti-FXa activity measurement. Innovance heparin (Siemens Healthineers, Marburg, Germany) calibrated with rivaroxaban and apixaban calibrators (Hyphen BioMed, Neuville- sur-Oise, France) was used for quantitative determination of FXa inhibitors. Results: Analysis showed good agreement between LMWH calibrated and rivaroxaban calibrated activity (κ = 0.76) and very good agreement with apixaban calibrated anti-Xa activity (κ = 0.82), respectively. Low molecular weight heparin anti-FXa activity cut-off values of 0.05 IU/mL and 0.1 IU/ mL are suitable for excluding the presence of clinically relevant concentrations (< 30 ng/mL) of rivaroxaban and apixaban, respectively. Concentrations above 300 ng/mL exceeded upper measurement range for LMWH anti-FXa assay and cannot be determined by this method. Conclusion: Low molecular weight heparin anti- FXa assay can be used in emergency clinical conditions for ruling out the presence of clinically relevant concentrations of rivaroxaban and apixaban. However, use of LMWH anti-FXa assay is not appropriate for their quantitative determination as an interchangeable method.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti, Javno zdravstvo i zdravstvena zaštita



POVEZANOST RADA


Projekti:
HRZZ-IP-2016-06-8208 - Novi oralni antikoagulansi: povezanost koncentracije lijeka i antikoagulantnog učinka (LAB-NOAC) (Margetić, Sandra, HRZZ - 2016-06) ( POIROT)

Ustanove:
Farmaceutsko-biokemijski fakultet, Zagreb,
KBC "Sestre Milosrdnice"

Citiraj ovu publikaciju

Margetić, Sandra; Ćelap, Ivana; Delić Brkljačić, Diana; Pavlović, Nikola; Šupraha Goreta, Sandra; Kobasić, Ivana; Lovrenčić- Huzjan, Arijana; Bašić Kes, Vanja
Chromogenic anti-FXa assay calibrated with low molecular weight heparin in patients treated with rivaroxaban and apixaban: possibilities and limitations // Biochemia Medica: The journal of The Croatian Society of Medical Biochemistry and Laboratory Medicine, 30 (2020), 1; 010702, 9 doi:10.11613/BM.2020.010702 (međunarodna recenzija, članak, znanstveni)
Margetić, S., Ćelap, I., Delić Brkljačić, D., Pavlović, N., Šupraha Goreta, S., Kobasić, I., Lovrenčić- Huzjan, A. & Bašić Kes, V. (2020) Chromogenic anti-FXa assay calibrated with low molecular weight heparin in patients treated with rivaroxaban and apixaban: possibilities and limitations. Biochemia Medica: The journal of The Croatian Society of Medical Biochemistry and Laboratory Medicine, 30 (1), 010702, 9 doi:10.11613/BM.2020.010702.
@article{article, year = {2020}, pages = {9}, DOI = {10.11613/BM.2020.010702}, chapter = {010702}, keywords = {apixaban, DOAC, factor Xa inhibitors, LMWH, rivaroxaban}, journal = {Biochemia Medica: The journal of The Croatian Society of Medical Biochemistry and Laboratory Medicine}, doi = {10.11613/BM.2020.010702}, volume = {30}, number = {1}, issn = {1330-0962}, title = {Chromogenic anti-FXa assay calibrated with low molecular weight heparin in patients treated with rivaroxaban and apixaban: possibilities and limitations}, keyword = {apixaban, DOAC, factor Xa inhibitors, LMWH, rivaroxaban}, chapternumber = {010702} }
@article{article, year = {2020}, pages = {9}, DOI = {10.11613/BM.2020.010702}, chapter = {010702}, keywords = {apixaban, DOAC, factor Xa inhibitors, LMWH, rivaroxaban}, journal = {Biochemia Medica: The journal of The Croatian Society of Medical Biochemistry and Laboratory Medicine}, doi = {10.11613/BM.2020.010702}, volume = {30}, number = {1}, issn = {1330-0962}, title = {Chromogenic anti-FXa assay calibrated with low molecular weight heparin in patients treated with rivaroxaban and apixaban: possibilities and limitations}, keyword = {apixaban, DOAC, factor Xa inhibitors, LMWH, rivaroxaban}, chapternumber = {010702} }

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE


Citati





    Contrast
    Increase Font
    Decrease Font
    Dyslexic Font